151 related articles for article (PubMed ID: 30971332)
1. FR-Ciclosporin as a First-Line Treatment in Epidermal Necrolysis.
Morgado-sCarrasco D; Fustà-Novell X; Iranzo P
Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):601-603. PubMed ID: 30971332
[No Abstract] [Full Text] [Related]
2. RF - Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Treatment Update.
de Quintana-Sancho A; Rubio-Lombraña M; Guergue Díaz-de-Cerio O; Barrutia-Borque A
Actas Dermosifiliogr; 2016 Apr; 107(3):247-8. PubMed ID: 26138285
[No Abstract] [Full Text] [Related]
3. Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study.
Mohanty S; Das A; Ghosh A; Sil A; Gharami RC; Bandyopadhyay D; Das NK
Indian J Dermatol Venereol Leprol; 2017; 83(3):312-316. PubMed ID: 28366923
[TBL] [Abstract][Full Text] [Related]
4. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.
Valeyrie-Allanore L; Wolkenstein P; Brochard L; Ortonne N; Maître B; Revuz J; Bagot M; Roujeau JC
Br J Dermatol; 2010 Oct; 163(4):847-53. PubMed ID: 20500799
[TBL] [Abstract][Full Text] [Related]
5. Selective Use of Cyclosporine for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis May Exclude Patients with Poor Prognostic Factors.
Noe MH; Mostaghimi A; Rosenbach M; Shinkai K; Micheletti RG
J Invest Dermatol; 2018 Sep; 138(9):2068-2072. PubMed ID: 29559345
[No Abstract] [Full Text] [Related]
6. Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate.
Hashim N; Bandara D; Tan E; Ilchyshyn A
Acta Derm Venereol; 2004; 84(1):90-1. PubMed ID: 15040495
[No Abstract] [Full Text] [Related]
7. Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center.
Lee HY; Fook-Chong S; Koh HY; Thirumoorthy T; Pang SM
J Am Acad Dermatol; 2017 Jan; 76(1):106-113. PubMed ID: 27717620
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Gilbert M; Scherrer LA
Dermatol Ther; 2019 Jan; 32(1):e12758. PubMed ID: 30285308
[TBL] [Abstract][Full Text] [Related]
9. Use of cyclosporine for the treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.
Shah R; Chen ST; Kroshinsky D
J Am Acad Dermatol; 2021 Aug; 85(2):512-513. PubMed ID: 30630021
[No Abstract] [Full Text] [Related]
10. Stevens-Johnson syndrome in childhood.
Blanco N; Gutiérrez B; Valls I; Puertas D; Martín C; Rivera M; Hernández Á; Torrelo A
Arch Soc Esp Oftalmol; 2017 May; 92(5):241-244. PubMed ID: 27899204
[TBL] [Abstract][Full Text] [Related]
11. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.
Kirchhof MG; Miliszewski MA; Sikora S; Papp A; Dutz JP
J Am Acad Dermatol; 2014 Nov; 71(5):941-7. PubMed ID: 25087214
[TBL] [Abstract][Full Text] [Related]
12. Severe Cutaneous Drug Reactions: Do Overlapping Forms Exist?
Horcajada-Reales C; Pulido-Pérez A; Suárez-Fernández R
Actas Dermosifiliogr; 2016; 107(1):23-33. PubMed ID: 26520037
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine for SJS/TEN: a case series and review of the literature.
Reese D; Henning JS; Rockers K; Ladd D; Gilson R
Cutis; 2011 Jan; 87(1):24-9. PubMed ID: 21323097
[TBL] [Abstract][Full Text] [Related]
14. Use of Intravenous Immunoglobulins and Systemic Corticosteroids in Patients with Toxic Epidermal Necrolysis: Experience of a Hospital in Mexico City.
Barrera-Ochoa CA; Marioni-Manríquez S; Cortázar-Azuaje AM; Quijada-Ucelo ZM; Saba-Mussali AJ; Vega-Memije ME
Actas Dermosifiliogr; 2022 Mar; 113(3):294-299. PubMed ID: 35526921
[TBL] [Abstract][Full Text] [Related]
15. New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis.
Roujeau JC; Mockenhaupt M; Guillaume JC; Revuz J
J Invest Dermatol; 2017 Oct; 137(10):2047-2049. PubMed ID: 28941473
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective.
Gupta LK; Martin AM; Agarwal N; D'Souza P; Das S; Kumar R; Pande S; Das NK; Kumaresan M; Kumar P; Garg A; Singh S
Indian J Dermatol Venereol Leprol; 2016; 82(6):603-625. PubMed ID: 27716721
[TBL] [Abstract][Full Text] [Related]
17. Intravenous cyclosporine in treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis: A case series.
Vinay K; Kaushik A; Kumaran MS; Parsad D
Dermatol Ther; 2019 Jul; 32(4):e12957. PubMed ID: 31070856
[No Abstract] [Full Text] [Related]
18. Cyclosporine in toxic epidermal necrolysis: a brief review of the emerging therapeutic modality.
Kumar P; Kanti Das N
Dermatol Online J; 2016 Oct; 22(10):. PubMed ID: 28329582
[TBL] [Abstract][Full Text] [Related]
19. Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone.
Aihara Y; Ito R; Ito S; Aihara M; Yokota S
Pediatr Int; 2007 Oct; 49(5):659-62. PubMed ID: 17875095
[No Abstract] [Full Text] [Related]
20. Pediatric toxic epidermal necrolysis treated successfully with infliximab.
Chafranska L; Saunte DM; Behrendt N; Nygaard U; Christensen RJ; Sand C; Jemec GB
Pediatr Dermatol; 2019 May; 36(3):342-345. PubMed ID: 30834560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
